Kits Eyecare (TSX: KITS) has raised its guidance for the third quarter following a strong week of sales to close out the month of August.
The eyecare company reportedly saw $3.5 million in sales for the week ended August 31, 2024, a record-breaking week for the company. As a result, the company has now declared that Q3 revenue will exceed the previously provided range of $39 to $41 million.
The revised outlook is said to call for over 32% growth in year over year topline revenue.
Adjusted EBITDA meanwhile is expected to remain in a range between 3% and 5% of revenue.
Kits Eyecare last traded at $10.90 on the TSX.
Information for this story was found via the sources mentioned within the article. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
